Zhi Tong Cai Jing·2026-02-26 11:25Financial Performance - In Q4 2025, the company reported total global revenue of $1.5 billion, a year-on-year increase of 33% [1] - For the full year 2025, total global revenue reached $5.3 billion, reflecting a 40% year-on-year growth [1] - Adjusted net profit for Q4 2025 was approximately $225 million, a significant increase of 1,297% year-on-year [1] - The full year adjusted net profit for 2025 was about $918 million, marking a return to profitability [1] - Free cash flow for Q4 2025 was $380 million, an increase of $397 million compared to the same period last year [1] - For the full year 2025, free cash flow totaled $942 million, an increase of $1.6 billion year-on-year [1] - The revenue guidance for the full year 2026 is projected to be between $6.2 billion and $6.4 billion [1] Product Performance - The global sales of Baiyueze (Zebutinib) in Q4 2025 reached $1.1 billion, a 38% year-on-year increase [1] - The annual global sales of Baiyueze for 2025 were $3.9 billion, representing a 49% growth compared to the previous year [1] - Global sales of Baizean (Trelatuzumab) in Q4 2025 were $18.2 million, an 18% increase year-on-year [1] - The total annual sales of Baizean for 2025 were $73.7 million, reflecting a 19% year-on-year growth [1] Strategic Insights - The strong financial performance in Q4 2025 and for the full year underscores the company's evolution as a leader in the global oncology treatment sector [2] - The company has established a durable competitive advantage in clinical development and production, supported by a differentiated R&D pipeline [2] - Baiyueze has solidified its position as a global leader in the BTK inhibitor space, with extensive regulatory approvals and strong clinical recognition [2] - The company is expanding the indications and reimbursement coverage for Baizean in major global markets [2] - With several cornerstone hematologic oncology products nearing commercialization and promising data from solid tumor pipelines, the company aims for sustainable global growth [2]